DuoBody-CD40x4-1BB (GEN1042)

Overview
DuoBody®-CD40x4-1BB (GEN1042) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab’s DuoBody technology. It is being co-developed under an agreement in which the companies share all costs and future profits for the product on a 50:50 basis. CD40 and 4-1BB were selected as targets to enhance both dendritic cells (DC) and antigen-dependent T-cell activation, using an inert DuoBody format.

Clinical studies

A Phase I/II clinical study of DuoBody-CD40 x4-1BB in solid tumors is ongoing.  For more information, visit clinicaltrials.gov.